泰索帝联合卡铂治疗晚期乳腺癌的临床观察  

The Clinical Observation of Docetaxel and Carboplatin in the Treatment of Advanced Breast Cancer

作　　者：邸旭[1] 王新超[1] 王牧[1] 

机构地区：[1]天津市第四中心医院普外科,天津300140

出　　处：《肿瘤基础与临床》2006年第4期298-299,共2页journal of basic and clinical oncology

摘　　要：目的分析用泰索帝(Docetaxel,Taxotere)联合卡铂经静脉给药治疗晚期乳腺癌的毒副反应及初步疗效。方法18例晚期乳腺癌(Ⅲ或Ⅳ期)患者采用泰索帝75mg/m2联合卡铂100mg/m2静脉推注化疗,观察每次化疗后的毒副反应,完成6个疗程者观察疗效。结果15例完成全部6个疗程化疗,完全缓解(CR)8例,占53%(8/15),部分缓解(PR)3例,占20%(3/15),总有效率73%(11/15)。无一例因药物毒副反应停止化疗。结论泰索帝联合卡铂治疗晚期乳腺癌有较好疗效,可以作为一线药物应用于临床。Objective To analyze the treatment results and adverse effect of Docetaxel and Carboplatin that was administered by iv infusion in the treatment of the cases with advanced breast cancer. Methods Combination chemotherapy containing Docetaxel and Carboplatin was used in 18 patients （ Ⅲ or Ⅳ stage） with advanced breast cancer, the Docetaxel at a dose of 75 mg/m^2 and Carboplatin at a dose of 100 mg/m^2 were administered. We evaluated the adverse effect of each combination chemotherapy and the treatment results of the patients who had finished all of the 6 courses. Results 15 of the 18 patients finished 6 courses. The total response rate （RR） was 73 % （11/15）, with 8（53 % ） complete remission （CR）, 3 （20%） partial remission（PR）, No one of the 18 patients was contraindicated to chemotherapy by the adverse effect. Conclusions Docetaxel and Carboplatin were effective on treatment of advanced breast cancer and could be used as the first selection.

关 键 词：晚期乳腺癌 泰索帝 卡铂 联合化疗 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]